AstraZeneca's new antibody has been given a significant reduction in the risk of developing severe Covid-19 or death in patients with mild-to-moderate symptomatic COVID-19 - according to the British Medical Journal (BMJ) .
Source: investegate.co.ukPublished on 2021-10-11
Related news
- AZD7442 reduced risk of developing severe COVID - 19 or death in TACKLE Phase III outpatient treatment trial
- EVUSHELD long - acting antibody combination retains neutralizing activity against Omicron variant in studies from Oxford and Washington Universities
- AstraZeneca plc ( via Public ) / AZD7442 reduced risk of developing severe COVID - 19 or death in TACKLE Phase III outpatient treatment trial
- Safety and immunogenicity of 2 - dose heterologous Ad26 . ZEBOV , MVA - BN - Filo Ebola vaccination in children and adolescents in Africa : A randomised , placebo - controlled , multicentre Phase II clinical trial
- New Analyses of Two AZD7442 COVID - 19 Phase III Trials in High - Risk Populations Confirm Robust Efficacy and Long - Term Prevention
- Continued attendance in a PrEP program despite low adherence and non - protective drug levels among adolescent girls and young women in Kenya : Results from a prospective cohort study
- Evusheld long - acting antibody combination retains neutralising activity against Omicron variant in independent FDA study
- EVUSHELD long - acting antibody combination retains neutralizing activity against Omicron variant in studies from Oxford and Washington Universities